In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read MoreIn a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...
Read MoreIn a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...
Read MoreIn a nutshell This study evaluated three different chemotherapy regimens with varying doses of doxorubicin (Adriamycin) for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CEOP70 could be safely used instead of R-CHOP50, while R-CEOP90 may be recommended for younger patients. Some background DLBCL is one of the most...
Read MoreIn a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....
Read MoreIn a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read MoreIn a nutshell This study examined if a modified version of doxorubicin (Adriamycin) in ABVD chemotherapy was safe and effective in patients with Hodgkin’s lymphoma who had heart disease. This study found that this regimen was safer and just as effective as conventional ABVD. Some background Hodgkin’s lymphoma (HL) is a cancer of white...
Read MoreIn a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...
Read MoreIn a nutshell This study compared RTXM83 to rituximab (Rituxan) to see if it is as effective and safe for patients with diffuse large B-cell lymphoma. This study concluded that RTXM83 is as effective and safe as rituximab. Some background Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin’s lymphoma. This type...
Read MoreIn a nutshell This trial is investigating the effectiveness of adding chemotherapy drug venetoclax to a standard chemotherapy treatment for patients with acute myelogenous leukemia (AML). The main outcome for this study would be the maximum amount of the drug that gives the most benefits to patients and the effectiveness of the drug. This study...
Read MoreIn a nutshell This trial is examining the effectiveness of crenolanib after salvage chemotherapy for relapsed or unresponsive acute myeloid leukemia (AML) with FLT3 activating mutations. The main outcome would be survival without complications from leukemia 3 years after the treatment has finished. The details AML is a type of blood...
Read MoreIn a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...
Read More
